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Abstract
Background: MHC class I proteins are partly responsible for shaping the magnitude and focus of the adaptive
cellular immune response. In humans, conventional wisdom suggests that the HLA-A, -B, and -C alleles are equally
expressed on the majority of cell types. While we currently have a thorough understanding of how total MHC class
I expression varies in different tissues, it has been difficult to examine expression of single MHC class I alleles due
to the homogeneity of MHC class I sequences. It is unclear how cDNA species are expressed in distinct cell subsets
in humans and particularly in macaques which transcribe upwards of 20 distinct MHC class I alleles at variable
levels.
Results: We examined MHC gene expression in human and macaque leukocyte subsets. In humans, while we
detected overall differences in locus transcription, we found that transcription of MHC class I genes was consistent
across the leukocyte subsets we studied with only small differences detected. In contrast, transcription of certain
MHC cDNA species in macaques varied dramatically by up to 45% between different subsets. Although the Mafa-
B*134:02 RNA is virtually undetectable in CD4+ T cells, it represents over 45% of class I transcripts in CD14+
monocytes. We observed parallel MHC transcription differences in rhesus macaques. Finally, we analyzed expression
of select MHC proteins at the cell surface using fluorescent peptides. This technique confirmed results from the
transcriptional analysis and demonstrated that other MHC proteins, known to restrict SIV-specific responses, are also
differentially expressed among distinct leukocyte subsets.
Conclusions: We assessed MHC class I transcription and expression in human and macaque leukocyte subsets.
Until now, it has been difficult to examine MHC class I allele expression due to the similarity of MHC class I
sequences. Using two novel techniques we showed that expression varies among distinct leukocyte subsets of
macaques but does not vary dramatically in the human cell subsets we examined. These findings suggest
pathogen tropism may have a profound impact on the shape and focus of the MHC class I restricted CD8+ T cell
response in macaques.
Background
MHC class I genes are critical to the development of the
cellular immune response. The products of these genes
are cell surface glycoproteins expressed on nearly every
nucleated cell. These molecules present short fragments of
endogenous proteins to surveillance CD8+ T cells. Once a
cell becomes cancerous or is infiltrated by an intracellular
pathogen, MHC class I proteins present these foreign
peptide fragments to CD8+ T cells. CD8+ T cells can
secrete cytokines and kill cells presenting specific MHC-
antigen complexes, preventing the spread of a pathogen or
tumor development. Both intracellular pathogens and
tumors subvert CD8+ T cell killing by altering MHC class
I presentation. Decreasing surface expression of MHC
class I proteins renders infected cells less visible to CD8+
T cells, allowing pathogens and tumors to survive and
replicate undetected. Thus, developing a clear picture of
MHC expression on the cell surface is a critical compo-
nent of understanding the body’s response to cancer and
infection.
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The classical human MHC class I loci are termed
HLA-A, -B and -C. In contrast to the HLA, macaque
MHC class I genes have experienced multiple gene
duplications and deletions. Although macaques lack a
homologue of the HLA-C locus, they have an expanded
number of MHC class IA and IB loci encoding up to 19
distinct class I transcripts on a single haplotype [1-4].
Like humans, specific macaque MHC alleles have been
associated with both susceptibility and resistance to dis-
ease [3].
The repertoire of MHC alleles and the level of expres-
sion of each of these alleles is a critical aspect of how the
immune system responds to pathogens. HIV and other
intracellular pathogens are known to preferentially infect
distinct leukocyte subsets, thus the particular MHC class
I alleles expressed by infected cells may define the reper-
toire of immune responses generated by an individual
[5-7]. Additionally, it was recently demonstrated that
MHC class I proteins can act as virus entry receptors [8].
In this circumstance, MHC expression may help define
the tropism of a pathogen. Finally, the level of MHC
expression on the cell surface is also critical to natural
killer cell signaling where MHC molecules can act as
activating or inhibitory ligands for natural killer cells [9].
Basal expression levels of certain MHC may determine
how the body responds to pathogens that subvert MHC
presentation. These facts indicate that a thorough exami-
nation of MHC expression is critical to understanding
the body’s susceptibility and response to pathogen [10].
Furthermore, MHC class I transcript expression in maca-
ques is particularly interesting considering the large
number of potential transcripts being expressed by a
single cell.
It is difficult to reconcile macaque expression of more
than three-dozen distinct MHC class I sequences pro-
vided our current understanding of cellular immunity.
Researchers classically view expression of MHC as a bal-
ance between having sufficient alleles to generate a diver-
sity of responses, and having too many alleles which may
result in negative thymic selection of otherwise effective
and important responses [1]. It remains unclear how
macaques maintain expression of, at least, 10 MHC class
I alleles while sustaining a functional and diverse CD8+
T cell response. Recent studies from the macaque
revealed that MHC class I molecules expressed at low
levels in the macaque PBMC do not appear to contribute
to the restriction of SIV-specific CD8+ T cell responses
[11]. These results demonstrate that we do not under-
stand the function of the alleles expressed at lower levels
or that we have simply not identified the tissues in which
these alleles are expressed at higher levels.
While much is known about total MHC class I
expression on individual cells, quantifying the contribu-
tion of individual alleles to overall expression is much
more difficult. Thus far, almost all expression studies
have relied upon using artificial expression of MHC
class I alleles in suitable MHC null cell lines and pan-
MHC class I antibodies [12-15]. The recent introduction
of quantitative real-time PCR assays that make it possi-
ble to compare HLA-A, -B, and -C locus-specific tran-
scription in normal human tissues have provided at
least preliminary evidence for preferential transcription
of the HLA-B locus in some individuals’ PBMC [16].
Alternatively, researchers have used immortalized cell
lines to study MHC class I expression. These studies are
removed from the in vivo environment and rely on over-
simplification of the natural cellular MHC class I milieu.
Furthermore, immortalization may depend on techni-
ques, like viral infection, that alter MHC class I expres-
sion. It was previously demonstrated in mice that the
presence or absence of certain alleles can affect the sur-
face expression of alleles on the opposite haplotype and
ultimately change the pattern of cellular immune
responses generated by an individual [17]. This study
suggests that characterizing a given MHC class I allele
in isolation will, at best, provide an incomplete picture
of expression. More recently investigators have used
locus specific antibodies to interrogate HLA-C expres-
sion in HIV infected individuals [18]. Thomas et al.
found that individuals with highly expressed HLA-C
alleles maintained lower chronic phase HIV viral loads.
These results indicate that differences in MHC expres-
sion can be correlated with control of viral replication
and disease pathogenesis.
Previous studies have not examined how expression of
MHC class I alleles varies among cell types such as indi-
vidual leukocyte subsets ex vivo. We examined expression
of MHC in both human and macaque leukocyte subsets.
Mauritian cynomolgus macaques (MCM) have limited
MHC diversity providing an opportunity to study animals
that are homozygous or heterozygous within the MHC
region [19-23]. Here we use high-throughput pyrose-
quencing of a variable region of the MHC class I
sequence to assess relative transcript abundance of speci-
fic alleles in purified leukocyte subsets [22]. We did not
observe large differences in MHC class I transcription
among the leukocyte subsets in the humans that we
examined. In contrast, we found that transcription varied
for three MCM MHC class I genes, with one cDNA spe-
cies differing as much as 45% among distinct leukocyte
subsets. We also identified differentially expressed tran-
scripts in the rhesus macaque that varied up to 15%
among different leukocyte subsets. Moreover, we
observed that this variability in transcript number equa-
ted to differences in protein expression of several alleles
including those that restrict SIV-specific CD8+ T cell
responses. To our knowledge, this is the first example of
differential expression of classical MHC class I
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Two HIV-negative subjects were enrolled in Madison
through the University of Wisconsin Hospital. This
study was approved by the Wisconsin Health Sciences
Institutional Review Board.
Animal Care and Use
Animals were cared for by the Wisconsin National Pri-
mate Research Center (WNPRC) according to protocols
approved by the University of Wisconsin Research Animal
Resources Center review committee. A table of the ani-
mals used in this study can be found in Figure 1. Sequen-
cing analysis of MCM was performed prior to animal
infections. Rhesus animals r03047, and r98030 were SIV
positive while animals r02033 and rh2349 was uninfected
at the time of this study. Protein expression studies were
performed after animals were SIV+ (Figure 1). We used a
total of twenty-three Mauritian cynomolgus macaques and
four rhesus macaques.
Microsatellite Typing of Mauritian Cynomolgus Macaques
Animals were haplotyped using a previously described
panel of microsatellite markers spanning the ~5 Mb geno-
mic MHC region [23]. These haplotypes were used to
infer the MHC genotypes of the animals used in this
study.
Cell Lines
Transfectant cell lines were created as previously
described [19]. Cells were maintained in complete
media. Transfectants were maintained under G418
(Mediatech, Manassas, VA) drug selection.
Cell Separations
Blood was drawn from macaques or human subjects into
EDTA tubes at the WNPRC or University of Wisconsin
Hospital respectively and layered over Ficoll-Paque Plus
(GE Healthcare Bioscience, Uppsala, Sweden); peripheral
blood mononuclear cells (PBMC) were isolated by density
centrifugation. We then split the PBMC into several equal
aliquots for each leukocyte separation. CD8+ T cells were
isolated using an anti-CD8ß-phycoerythrin (PE) monoclo-
nal antibody (Beckman Coulter, Fullerton, CA) and anti-
PE beads with LS columns (Miltenyi, Auburn, CA). CD4,
CD14, CD16, and CD20 cell separations used the single-
step nonhuman primate or human kits available from Mil-
tenyi. As each leukocyte subset was isolated, we froze cells
in RNAlater (Ambion, Foster City, CA) and set aside ali-
quots of each sample for staining of cell surface markers.
Each sample was stained with CD14 Fluorescein
isothiocyanate (FITC) (BD Biosciences, San Jose, CA),
CD4 phycoerythrin Cy5 (PE Cy5), CD19 phycoerythrin
Cy7 (PE Cy7) or CD3 PE Cy7; CD8 Pacific Blue, CD20
allophycocyanin (APC), W6/32 APC or CD4 APC; CD3
Alexa Fluor 700 (A700) or CD14 A700 and CD8B PE
(Beckman Coulter, Fullerton, CA), CD16 PE or CD20 PE
and run on an LSRII flow cytometer (BD Biosciences, San
Jose, CA). We analyzed results with FlowJo software ver-
sion 8.8.6 and 9.2 (TreeStar, Ashland, OR) to assess the
purity of the leukocyte populations.
cDNA-PCR and Pooling Strategy
We isolated RNA from each cell population using either
the Allprep DNA/RNA Mini Kit or RNeasy Mini Kit
(Qiagen, Germantown, MD). We synthesized cDNA
from total cellular RNAs using a Superscript III First-
Strand Synthesis System (Invitrogen, Carlsbad, CA). We
created primary cDNA-PCR amplicons spanning 190 bp
of exon 2 of macaque class I sequences with high-fidelity
Phusion polymerase (New England Biolabs, Ipswich, MA
as described previously [22]. For the cynomolgus maca-
ques, each PCR primer contained one of 12 distinct 10-
bp MID tags along with adaptor sequences for Roche/
454 sequencing. After purification, we normalized pri-
mary amplicons to equimolar concentrations and pooled
groups of 12 amplified products for GS FLX analysis. For
the rhesus macaques each PCR primer contained one of
32 distinct 10-bp MID tags along with adaptor sequences
for Roche/454 Titanium sequencing. After purification,
we normalized primary amplicons to equimolar concen-
trations and pooled groups of 32 amplified products for
GS Junior analysis. For the humans, each PCR primer
contained one of 16 distinct 10-bp MID tags along with
adaptor sequences for Roche/454 sequencing. After puri-
fication we normalized primary amplicons to equimolar
concentrations and pooled groups of 16 amplified pro-
ducts for GS Junior analysis [24]. Each cell population
was amplified with two different MID tags to minimize
the effects of primer bias.
Emulsion PCR and Pyrosequencing
For the cynomolgus macaque sequencing, we performed
the emulsion PCR and pyrosequencing steps with GS
FLX instruments (Roche/454 Life Sciences, Branford,
CT) using standard chemistry according to the manufac-
turer’s specifications (454 Life Sciences); the work was
performed at the University of Illinois at Urbana-Cham-
paign High-Throughput Sequencing Center and North-
western University Division of Infectious Disease. We
sequenced each amplicon pool of twelve products in
one-sixteenth of a 70 × 75 mm Standard PicoTiterPlate
(Roche/454 Life Sciences).
We performed the rhesus macaque and human
sequencing, emulsion PCR and pyrosequencing steps
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with the GS Junior instrument (Roche/454 Life Sciences)
using Titanium chemistry according to the manufac-
turer’s specifications. We sequenced this amplicon pool
of 32 and 16 products in two separate GS Junior 21 ×
45 mm PicoTiterPlates (Roche/454 Life Sciences).
Data Analysis
After image processing and base calling with GS FLX
software (454 Life Sciences), we binned high-quality
sequence reads by their respective MID tags and
assembled the reads into contigs with 100% identity for
a
b
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M1 M2 M3 M4 M7
A1*063:01 A1*063:01 A1*063:02 A1*031:01 Mafa-A1*060:05
A2*05:01 A2*05:01 A2*05:11 A2*05:04 Mafa-A5*30:01
A4*01:01 A4*01:01 A4*01:01 A5*30:01
Mafa-B*144:02 Mafa-B*148:01 Mafa-B*011:01 Mafa-B*147:01 Mafa-B*072:02
Mafa-B*134:02 Mafa-B*019:01 Mafa-B*075:01 Mafa-B*088:01 Mafa-B*044:04
Mafa-B*104:01 Mafa-B*150:01 Mafa-B*079:01 Mafa0B*027:02 Mafa-B*164:02
Mafa-B*064:01 Mafa-B*079:03 Mafa-B*098:05 Mafa-B*060:05:01 Mafa-B*060:06
Mafa-B*057:02 Mafa-B*098:01 Mafa-B*165:01 Mafa-B*051:03 Mafa-B*166:01






Figure 1 Cynomolgus macaques used in the study. a) Each column represents a different haplotype with previously defined MHC class I
alleles. b) Animals used throughout the study. Haplotypes are indicated to the left of the animal name. An × is marked in columns to indicate
whether the animal was used in the 454 analysis, fluorescent peptide analysis or both.
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each macaque using SeqMan Pro Version 8.0.2 (DNAS-
TAR). We performed BLASTN or mosaik http://bioinfor-
matics.bc.edu/marthlab/Mosaik analyses for the resulting
contigs against a custom in-house database of macaque
or human MHC class I sequences. Then, we compared
transcript abundance levels between individual subsets in
macaques. For normalization of each subset for statistical
analysis, we divided the combined number of sequence
reads for each distinct class I sequence from both MID
tags by the total combined number of sequence reads for
both MID tags. MHC class I nomenclature has recently
been revised to reflect similar allelic lineages between
closely related macaque species [25].
Secreted MHC Production
To produce secreted MHC molecules, a-chain cDNAs of
Mafa-B*134:02, were modified at the 3’ end by PCR muta-
genesis to delete exons 5-7 encoding the transmembrane
and cytoplasmic domains and to add a thirty base-pair tail
encoding the 10 amino acid rat very low density lipopro-
tein receptor (VLDLr), SVVSTDDDLA, for purification
purposes [26]. sMHC-VLDLr were cloned into the mam-
malian expression vector pcDNA3.1(-) Geneticin (Invitro-
gen) and then sequenced to insure fidelity of each clone.
721.221 cells were transfected with sMHC Mafa-
B*134:02TVLDLr by electroporation. After 48 hours
incubation, cells were plated in 96 well plates (Falcon)
in RPMI 1640 containing antibiotic. Transfectants were
tested for production of sMHC molecules by a VLDLr
specific ELISA [27]. Positive wells were subcloned into
96 well plates (Falcon) by limiting dilution. Individual
wells with clonal cell populations were tested for the
production of sMHC and high producers were expanded
for inoculation into bioreactors in an AccuSyst-Maximi-
zer (Biovest International, Minneapolis, MN).
Peptide Purification
Approximately 25 mg of Mafa B*134:02TVLDLr mole-
cules from the 721.221 cell line were purified over an affi-
nity column composed of anti-VLDLr antibody (ATCC
clone CRL-2197) coupled to CNBr activated Sepharose
4B (GE Healthcare, Piscataway, NJ). sMHC molecules
were then eluted in 0.2 N acetic acid, brought up to 10%
acetic acid, and heated to 78°C for 10 min. Peptides were
separated from heavy and light chains by ultrafiltration in
a stirred cell with a 3kDa molecular weight cutoff cellu-
lose membrane (Millipore, Bedford, MA). The peptide
batch was flash frozen and lyophilized. The peptides were
then reconstituted in 10% acetic acid.
Determination of Peptide Binding Motif
Following isolation, 10% of the peptide pool was sub-
jected to 14 rounds of N-terminal sequencing by Edman
degradation. A motif was generated by calculating the
fold increase of each amino acid over the prior round. A
hierarchy was determined based on the amino acid com-
position at each position [28].
Reverse Phase HPLC
Peptides were reverse phase HPLC fractionated using a
Jupiter Proteo C12 column (Phenomenex, Torrance,
CA) on a Paradigm MG4 system (Michrom Biore-
sources, Auburn, CA). A standard CH3CN gradient was
employed to generate approximately 40 peptide contain-
ing fractions. UV absorption was monitored at 215 nm.
Mass Spectrometric Analysis
Peptide fractions were concentrated to dryness and
reconstituted in 20 μl of nanospray buffer composed of
50% Methanol, 50% H20, and 0.5% Acetic Acid. Nano-
electrospray capillaries (Proxeon, Denmark) were loaded
with 1 μl of each peptide fraction and infused at 1100 V
on a Q-Star Elite quadrupole mass spectrometer with a
TOF (time of flight) detector (Applied Biosystems, Foster
City, CA). Ion maps were generated for each fraction in a
mass range of 300-1200 amu. Independent Data Acquisi-
tion was used to select ions for fragmentation by tandem
mass spectrometry (MS/MS). An amino acid sequence
was assigned using the publicly available, web based
MASCOT (Matrix Science Ltd., London, UK) and/or de
novo sequencing.
Fluorescent Peptide Staining
Fluorescent peptides were synthesized by Dr. Gary Case at
the University of Wisconsin Biotechnology Center and by
ProImmune Ltd. (Bradenton, FL). Fluorescein molecules
were conjugated to lysine residues within each synthesized
peptide. Two versions of each peptide with fluorescein
conjugated lysine residues at two separate positions
excluding the anchor residues were tested for each pep-
tide. The peptides used in these experiments were Mafa-
B*134:02 restricted NH2-GVFGFP(K-fluor)GR-COOH
(fGR9), non-specific peptide NH2-YR(K-fluor)WIQLGL-
COOH, Mafa-B*075:01 restricted NH2-ALPE(K-fluor)
FTEL-COOH (fAL9), and Mafa-A1*063:01 NH2-SPIR(K-
fluor)LPHW-COOH (fSW9).
Cells were aliquoted and then peptide was added at a
final concentration of 100 nM. After 24 hours at 4°C cells
were stained with CD20 PE, CD4 PerCP, CD3 PE Cy7,
CD8 Pacific Blue, W6/32 APC, and CD14 A700. After 30
additional minutes of incubation at 4°C, the cells were
washed twice and fixed with 2% PFA. Relative expression
was calculated using the following formula (MFI ×/MFI
No Peptide) * 100 where × was fGR9, fAL9, or fSW9.
Statistics
In our sequencing analysis, we compared the frequency
of an allele across different cell types by a chi-square
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test. We compared relative protein expression between
select subsets in the M3 homozygous animals by a
repeated measures ANOVA and paired student’s T test
using GraphPad Prism, version 5.0a for Macintosh
(GraphPad Software, San Diego, CA http://www.graph-
pad.com). We used an unpaired student’s T test to com-
pare expression of Mafa-A1*063:01 across the different
haplotypes in CD3+ cells.
Results
MHC transcription in human leukocyte subsets
We used Ficoll density centrifugation to isolate PBMC
from the blood of two humans. Next, using magnetic
separations, we isolated several distinct leukocyte popu-
lations based on the presence of well-characterized sur-
face markers. We isolated CD4+, CD14+ and CD20+
cells to generally greater than 90% purity within the
lymphocyte gate (data not shown). We isolated RNA
from each separated subpopulation in addition to whole
PBMC. Next, we performed cDNA synthesis and used
universal MID-tagged primers to amplify a 581 bp frag-
ment of all MHC class I genes. Every subset was sub-
jected to two independent PCR amplifications with two
unique MID tags. We then prepared these samples for
pyrosequencing as previously described [22,24]. Finally
we compared the sequences against an HLA reference
database.
We created transcript profiles for each leukocyte subset
based on the percentage of total transcripts each unique
sequence constituted. We obtained an average of 3381
sequence reads per leukocyte subset. Next, we examined
transcription of each allele across the four leukocyte sub-
sets. There were small but significant differences in HLA
transcription amongst lymphocyte subsets (p < 0.001)
except for HLA-C*04 in the second individual (Figure 2).
However, between the two individuals there were not
consistent differences in transcription amongst different
subsets. For example, HLA-B alleles were not consis-
tently expressed at higher levels in any single subset.
CD14 cells appear to express lower levels of HLA-E than
the other cell types, but measurements in the second
individual were variable. In particular, the levels of HLA-
E detected in the second individual were not consistent
between the two MID tags used for CD20 cells. The
higher level of HLA-E detected using one MID tag in the
CD20 cells led to generally lower detectable levels of the
other HLA class I genes. The results demonstrate that
the analysis is semi-quantitative and that we cannot
determine whether one gene is transcribed at higher
levels or if other genes are transcribed at lower levels.
The first individual appears homozygous for HLA-A
alleles with our current sequence coverage. Using our
novel technique for examining MHC transcription, we
were able to confirm previous results demonstrating that
HLA-B is transcribed at higher levels in PBMC [16]. We
also examined the contribution of each subset to the
total PBMC (Figure 2c). We found that the percentage of
each subset in total PBMC was consistent between the
two individuals. These results do not discriminate
between increased transcription of one gene or decreased
transcription of the other MHC genes, therefore this
method measures relative transcript levels and not abso-
lute transcript levels. Nevertheless, these data confirm
that our technique yields results qualitatively similar to
those provided by qPCR.
Differential mRNA Transcription of Mafa-B*134:02 in
MHC-defined macaques
Next we examined transcription of MHC class I cDNA
species in macaques which can express three-fold more
distinct MHC class I transcripts than humans. We have
previously described methods for rapidly genotyping
MCM for their MHC haplotypes by microsatellite analy-
sis and we have characterized all major MHC class I
and class II alleles associated with these haplotypes
[21-23,25]. We identified animals that included homozy-
gotes and heterozygotes for MHC class I and class II
alleles (Figure 1). These animals contained the M1, M2,
M3, M4 and M7 haplotypes. Using MCM eliminated
potential issues arising from uncharacterized animal
genotypes and allowed us to study animals with defined
degrees of MHC matching, thus simplifying the analysis.
We used Ficoll-Hypaque density centrifugation to iso-
late PBMC from macaque blood. Next, using magnetic
separations, we isolated several distinct leukocyte popu-
lations based on the presence of well-characterized sur-
face markers. We isolated CD4+, CD8+, CD14+, CD16
+, and CD20+ cells to genearally greater than 90% pur-
ity within the lymphocyte gate (data not shown). Again,
we isolated RNA from whole PBMC in addition to each
separated subpopulation. Next, we performed cDNA
synthesis and used universal primers to amplify a short,
polymorphic 190 bp region of all MHC class I genes.
Every subset was subjected to two independent PCR
amplifications with two unique MID tags. We then pre-
pared these samples for pyrosequencing as previously
described [22]. Finally we compared the sequences
against an MCM MHC class I BLAST database. We
found all expected and previously discovered transcripts
in the macaques’ PBMC [22,25].
We created transcript profiles for each leukocyte subset
based on the percentage of total transcripts each unique
sequence constituted (Figure 3a). On average we identi-
fied 1342 reads per subset. We then compared MHC pro-
files between different subsets and noted that, while the
profiles were similar between CD8+, CD16+, CD20+ and
CD4+ cells, there was a clear difference between these
populations and the CD14+ cells and PBMC (Figure 3a).
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Patient CD4 CD14 CD20
Subject 1 41.5 4.4 14.5
Subject 2 41 5.4 14.8
Figure 2 Transcription of HLA in leukocyte subsets from two humans. We normalized sequence reads for each allele within each leukocyte
subset by dividing the number of reads from each class I sequence by the total number of reads identified from that subset. Plots show the
mean and points represent independent PCR reactions using distinct MID tags sequenced in a single run. Alleles were distinguished at the two-
digit level. a) Normalized transcript levels for the first subject. b) Normalized transcript levels for the second subject. Plots show both data points
and the mean. c) Percentage that each subset contributes to the whole PBMC. For CD20 cells, data points from the PCR reaction with MID 1 are
shown with red squares while those from MID 2 are shown with red squares and a black outline. A chi-square test was used to compare gene
transcription between subsets for each cDNA species.
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c Animal CD4 CD8 CD14 CD16 CD20
cy0158 42.6 29.8 14.7 ND 8.23
Figure 3 Differential transcription of Mafa-B*134:02 in animal cy0158. We normalized sequence reads for each allele within each leukocyte
subset by dividing the number of reads from each class I sequence by the total number of reads identified from that subset. As before, plots
show the mean, and each point represents the results of an independent PCR reaction with unique MID tag. a) Normalized transcript levels for
cy0158 in each subset. b) Normalized transcript levels for cy0158 after removing the contribution from Mafa-B*134:02 c) Percentage that each
subset contributes to the whole PBMC.
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Surprisingly, we observed that Mafa-B*134:02 transcripts
were dramatically over-represented in the CD14+ cells
compared to the other subpopulations (Figure 3a). In
contrast, Mafa-B*134:02 transcripts were nearly unde-
tectable in the CD8+ cells (Figure 3a). Again, we exam-
ined the contribution of each subset to the total PBMC
(Figure 3c). The Mafa-B*134:02 transcripts detected in
whole PBMC are consistent with the contribution of
monocytes to this heterogeneous population. The CD16+
cells also had intermediate levels of CD14+ transcription
which may explain the contribution of Mafa-B*134:02 to
this cell subset. We found that transcription of Mafa-
B*134:02 was significantly different between subsets (p <
0.0001). We repeated this experiment with cells from the
same animal as well as with an independent M1/M1 ani-
mal and found the results to be consistent among experi-
ments (data not shown).
Consistent transcription of other M1 alleles
The extremely high transcription of Mafa-B*134:02 in
the CD14+ cells made it difficult to assess the transcrip-
tion pattern of other alleles in this leukocyte subset. To
eliminate the effect of Mafa-B*134:02 transcription on
the rest of our analysis, we renormalized the transcript
percentages after eliminating the Mafa-B*134:02 reads
(Figure 3b). This analysis, which excluded the contribu-
tion of Mafa-B*134:02 to each sample, demonstrated
that the profiles were remarkably similar among subsets
in the absence of Mafa-B*134:02. Although Mafa-
B*104:01:01 was significantly elevated in the CD14+
cells (p < 0.0001), this difference was considerably less
than that seen with Mafa-B*134:02.
Differential MHC class I allele transcription in animals
with non-M1 haplotypes
Next we assessed transcription of Mafa-B*134:02 in an
animal that is heterozygous for the M1/M2 haplotypes.
We found that the pattern in Mafa-B*134:02 transcrip-
tion remained unchanged (Figure 4a). CD14+ cells con-
tinued to transcribe Mafa-B*134:02 at significantly
higher levels than any other cell subsets (p < 0.0001). As
expected, this heterozygous animal had reduced levels of
Mafa-B*134:02 transcripts in CD14+ cells compared to
the homozygous M1/M1 animals we analyzed. This sug-
gests that there is a gene dosage effect in MHC class I
transcription of this differentially expressed allele.
Next we examined MHC class I allele transcription in
animals with different MHC haplotypes. In the M2/M2
background we observed that there was indeed another
allele that was more highly transcribed in CD14+ cells
(Figure 4b). We found that Mafa-B*098:01:01 was tran-
scribed preferentially in the CD14+ cells (p < 0.0001). In
the M2/M2 animal we observed lower overall transcrip-













































































Figure 4 Differential transcription of alleles in animals with
different MHC haplotypes. We normalized sequence reads for
each allele within each leukocyte subset by dividing the number of
reads from each class I sequence by the total number of reads
identified from that subset. Points represent independent PCR
reactions using distinct MID tags sequenced in a single run.. a)
Expression of Mafa-B*134:02 in each leukocyte subset of M1/M2
animal cy0160. b) Expression of Mafa-B*098:01 in homozygous M2/
M2 animal cy0162. c) Expression of Mafa-B*088:01 in M3/M4
heterozygous animal cy0159. Plots show standard error of the
mean.
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suggesting that it may be a minor MHC class I allele.
However, it is important to remember that our measure
of transcription is semi-quantitative; primers could be
biased for certain cDNAs which ultimately biases the
dominance hierarchy. Nevertheless, the relative transcrip-
tion pattern of Mafa-B*098:01:01 was similar to that for
Mafa-B*134:02. These differences were also detected in
the M1/M2 heterozygous animal cy0160 (data not
shown). However, in this animal, the level of Mafa-
B*98:01:01 transcription was near our limit of detection.
In a final animal heterozygous for the M3/M4 haplo-
types, we identified an RNA transcript on the M4 haplo-
type that also follows this variable transcription pattern
(Figure 4c). In this animal, Mafa-B*088:01 was tran-
scribed at higher levels in CD14+ cells (p < 0.0001).
However, in this animal we did not identify an RNA
species that is differentially transcribed from the M3
haplotype. We did not analyze either of these haplotypes
in a homozygous macaque which may explain the
low level of Mafa-B*088:01 transcription and lack of dif-
ferentially transcribed alleles detected on the M3
haplotype.
Differential transcription of Mamu-B*072 g and Mamu-
B*098 g in the Indian rhesus macaque
Next we explored the transcription of classical MHC class
I alleles in Indian rhesus macaques to assess whether dif-
ferential transcription was conserved in a closely related
macaque species. Three animals expressed Mamu-B*008
while the fourth animal expressed Mamu-B*017; both of
these Mamu-B sequences are of special interested because
they are associated with exceptional control of SIV replica-
tion. From these four animals we isolated three separate
populations CD4+, CD14+, and CD20+ cells. We isolated
RNA from each of these subsets in addition to unsepa-
rated PBMC and synthesized cDNA. Next we amplified
the same variable region of the MHC class I gene as in the
experiments with the MCM. Every subset was subjected to
two independent PCR amplifications with two unique
MID tags. We used the Roche/454 GS Junior to sequence
these short products and obtained an average of 498 reads
per cell subpopulation.
While we did not find that Mamu-B*008 or Mamu-
B*017 were differentially transcribed, we found that, simi-
lar to our results in the MCM, Indian rhesus macaques
also have RNA species that are dominantly transcribed in
the CD14+ cells. All four animals expressed Mamu-B*072
g at higher levels in the CD14+ cells (Figure 5a-d). The
level of transcription amongst these animals varied, but
the pattern of transcription within each animal was simi-
lar. We also identified a transcript present in two animals,
Mamu-B*098 g, that is also dominantly transcribed in the
CD14+ cells (Figure 5e-f). In the whole PBMC, Mamu-
B*098 g borders on the limit of detection and would
potentially be undetectable if we did not specifically exam-
ine transcription in CD14+ cells. In sum, these results
indicate that differential transcription is conserved across
at least two macaque species, suggesting it may have a bio-
logical role in these animals.
Sequence motif identifies differentially expressed alleles
Next we sought to determine if these differentially
expressed transcripts had similarities in their sequences
that could explain the differential transcription. We
aligned the differentially expressed rhesus and cynomolgus
macaque sequences against all rhesus and cynomolgus
macaque MHC class I B full-length sequences. We identi-
fied a short sequence motif in exon 3 encoding the alpha 2
domain that was only present in these differentially
expressed RNAs (Table 1). We noted two synonymous dif-
ferences and two nonsynonymous differences in codon
162 that resulted in a methionine to glutamic acid substi-
tution in the predicted gene products. While we did not
detect transcription of Mafa-B*098:05 in the M3 heterozy-
gous animal, this cDNA species also shares this sequence
motif. Morover, every MCM haplotype contains a tran-
script that encodes this motif, but we were unable to
examine expression from a homozygous animal of each
haplotype. Therefore, while the transcripts that that are
differentially regulated appear to share this motif, it is
unclear whether every transcript with this motif will be
transcribed similar to the genes we identified here.
Approximately four percent of all macaque MHC class I B
alleles contain this sequence motif (Data not shown). This
motif may play a role in the regulation of gene expression
or may demonstrate that these RNA species evolved from
the same ancestral class I gene. Importantly, Mamu-B*072
is encoded by the Mamu-h2-B02 locus as previously
described by Daza-Vamenta et al. which is similar to
other classical MHC class I B genes [1].
Differential protein expression of Mafa-B*134:02
Although we demonstrated that certain MHC class I
sequences were regulated differentially at the transcript
level, it was not clear whether this differential transcrip-
tion lead to differences in protein expression. Previous
studies have demonstrated that gene dose alone does
not explain MHC class I allele surface expression in
mice that are the heterozygous progeny of homozygous
parents [17]. We optimized the use of fluorescein-conju-
gated peptides to assess the protein expression of alleles
with matching peptide motifs. We have previously
defined the binding motif for Mafa-A1*063:01 and
Mafa-B*075:01, and we defined the binding motif of
Mafa-B*134:02 using the same techniques (Figure 6a)
[19]. We identified several endogenous ligands of Mafa-
B*134:02 during this process (Figure 6b). We then chose
several peptides with high binding affinity and replaced
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Figure 5 Differential transcription of Indian rhesus macaque alleles. We normalized sequence reads for each allele within each leukocyte
subset by dividing the number of reads from each class I sequence by the total number of reads identified from that subset. Points represent
independent PCR reactions using distinct MID tags sequenced in a single run. Alleles were distinguished at the two-digit level. Normalized
expression of alleles in the Mamu-B*072 lineage across different subsets in animals a) r03047 b) r02033, c) r98030, and d) rh2349. Normalized
expression of alleles in the Mamu-B*098 lineage across different subsets in animals e) r03047 and f) r02033. Plots show standard error of the
mean.
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a non-anchor residue with a fluorescein-conjugated
lysine. We tested two of these peptides and chose the
peptide that bound with greater affinity. We used the
fluorescein conjugated Mafa-B*134:02 specific peptide
GR9 (fGR9) to assess protein expression of this MHC
class I allele and then followed the same procedure for
Mafa-A1*063:01 (fSW9) and Mafa-B*075:01 (fAL9).
We found that fGR9 was specific for Mafa-B*134:02 and
did not bind several other MHC class I alleles (data not
shown). Without testing a comprehensive panel of single
MHC class I expressing transfectants, it is impossible to
formally eliminate the possibility of fGR9 cross reactivity
with all Mafa class I alleles. We isolated PBMC from
twenty animals (Figure 2b). Six M3/M3 animals, one M4/
M7 and one M7/M7 lacked the Mafa-B*134:02 allele, six
animals were homozygous for the M1 haplotype contain-
ing Mafa-B*134:02, and six were M1/M3 heterozygous
animals. We normalized the level of peptide binding by
the level of MHC expression in each leukocyte subset and
then examined the percentage change compared to the no
Table 1 Sequence motif unique to CD14 specific class I
alleles
Class I B Consensus G C C G C G G A C A T G
CD14-Specific Expression
Consensus
• • T • • • • • T G A •
Class I B Translation Ala Ala Asp Met
CD14-Specific Expression
Translation
• • • Glu
All known full-length rhesus and cynomolgus macaque alleles were aligned. A
motif specific to the alleles transcribed highly in CD14+ cells was identified.
These CD14+ specific class I sequences were compared to the consensus
sequence of all cynomolgus and rhesus MHC class I B alleles.
1 2 3 4 5 6 7 8 9
Dominant RFLE
KAV
Strong I P D
Weak KFRNMA












ELPIVTPALR Importin alpha-2 subunit
EANNFLWPFK EIF3S10
ELFPAPILR FCRL
ELAVASFPK Cytochrome C oxidase
Figure 6 Binding motif defined for Mafa-B*134:02. a) Based on Edman degradation, residues were classified as dominant if they
demonstrated a ≥ 3.5-fold increase in picomoles over the previous round of sequencing, strong if they exhibited a 2.5 to 3.5-fold increase and
weak if they exhibited a 2.0 to 2.5 fold increase. b) Endogenous Mafa-B*134:02 ligand sequences identified by mass spectrometry.
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peptide controls. We found that when staining whole
PBMC with fGR9, only CD14+ cells from Mafa-B*134:02+
animals stained positive (Figure 7a). Animals that are
homozygous for Mafa-B*134:02 expressed the highest
levels of this protein followed by the heterozygous animals.
Levels of total MHC expression were also highest in the
CD14+ cells although there were not large differences
between the different animals. Additionally it appears that
all CD14+ cells express Mafa-B*134:02 (Figure 7c). Expres-
sion of this allele does not appear specific to a particular
CD14+ subset. These results indicate that the differences
we detected in transcript levels correlated with differences
in protein expression of Mafa-B*134:02.
We performed analogous expression assays for two
MHC alleles, Mafa-A1*063:01 which is present on the
M1, M2, and M3 haplotypes and Mafa-B*075:01 which is
present on the M3 haplotype. These two alleles are both
known to restrict SIV-specific CD8+ T cell responses.
We focused our statistical analysis on the M3/M3 ani-
mals which appeared to express the highest levels of
these MHC class I proteins. Interestingly, we found that
expression of Mafa-B*075:01 (p = 0.01) and Mafa-
A1*063:01 (p = 0.0009) was lower in CD14+ cells than
CD8+ cells (Figure 8). These results suggest high levels of
Mafa-B*134:02 are expressed in monocytes while other
alleles are expressed at reduced levels in this cell type.
We also identified differential expression of Mafa-
A1*063 between leukocyte subsets. We found that CD8+
T cells in M3/M3 animals express higher levels of Mafa-
A1*063:01 (p = 0.002) compared to CD4+ cells, demon-
strating that expression of several MHC proteins varies
by leukocyte cell types. Moreover, Mafa-A1*063:01,
which is present on both the M1 and M3 haplotype was
expressed at a higher level on M3/M3 CD3+ cells com-
pared to the M1/M1 (p = 0.004) and M1/M3 (p = 0.01)
CD3+ cells. It is possible that differences in the leader
peptide sequence between the Mafa-A1*063 transcripts
present on the M1 and M3 haplotypes may account for
these expression differences; however, we cannot elimi-
nate the possibility that the fluorescent peptide is cross-
reacting with another MHC class I allele on the M3.
However, these results show that MHC expression varies
dramatically by cell type and haplotype.
Discussion
Cancer researchers first began describing the MHC class
I loci over 50 years ago as they propagated tumors by
transplanting them between mice [29]. Examining
expression of particular alleles has classically been diffi-
cult due to the high degree of similarity among MHC
sequences. Systems using artificial expression are typi-
cally utilized to assess how alleles are expressed but
neglect how one allele can affect the expression of other
alleles and, thus, are removed from in vivo studies. We
assessed relative MHC class I transcript levels using a
recently described Roche/454 pyrosequencing approach
[22]. In humans, these studies identified greater tran-
scription of HLA-B in PBMC than HLA-A or HLA-C
[16]. However, they did not show differences in expres-
sion between the distinct leukocyte subsets. In contrast,
examinations of macaque MHC expression revealed dif-
ferent levels of several MHC class I transcripts in dis-
tinct leukocyte subsets of both MCM and rhesus
macaques. Furthermore, using a novel technique, we
confirmed that these differences in transcript abundance
translated to differences in protein expression of these
gene products.
We found that contrary to the paradigm of universal
expression of classic MHC class I alleles across different
cell types, macaque leukocyte subpopulations exhibited
differential expression of a subset of MHC class I
sequences. We detected both increased transcript levels
and increased protein expression of Mafa-B*134:02 in
CD14+ cells when compared to other leukocyte subsets.
Moreover, the only cells that appeared to bind a fluores-
cently labeled peptide specific for the Mafa-B*134:02
protein were monocytes suggesting this class I sequence
may have a unique function in these cells. It is important
to note that we did not examine other myeloid lineage
cells including dendritic cells and mature macrophages
by 454 analysis. It is entirely possible that other, more
refined subsets, may have comparable expression differ-
ences with this or other class I sequences.
We have not yet identified responses restricted by Mafa-
B*134:02 and were interested in studying expression of
alleles that we know restrict SIV-specific responses. When
we examined protein expression of two additional class I
sequences known to restrict SIV-specific CD8+ T cell
responses using fluorescent peptides we found that these
MHC proteins were also differentially expressed in distinct
leukocyte subsets. CD8+ T cells appear to express higher
levels of Mafa-A1*063:01 and Mafa-B*075:01 than CD4+
and CD14+ cells. CD14+ cells generally express lower
levels of these proteins providing evidence that Mafa-
B*134:02 is expressed at the expense of other MHC pro-
teins. Additionaly, we have not yet determined the
mechanism by which these alleles are differentially
expressed, but recent research by Kulkami et al. found
that HLA-C alleles are regulated by microRNAs [30].
It is not clear how these differences impact the immune
response generated by these different cell types. One pos-
siblilty is that this differential expression could variably
mold the immune response with the power to reshape
immunodominance hierarchies. Mouse influenza experi-
ments have previously demonstrated that the degree of
protein expression of MHC class I alleles can affect the
magnitude of CD8+ T cell immune responses generated
by the host [17]. A monocyte-tropic virus might generate
Greene et al. BMC Immunology 2011, 12:39
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Figure 7 Measuring protein expression of Mafa-B*134:02 by fluorescent peptide. a) A fluorescent peptide, fGR9, was used to measure
Mafa-B*134:02 expression in the PBMC. We looked at five different leukocyte subsets in 20 different animals. We determined relative expression
using the following formula: (MFI fGR9)/(MFI No Peptide). b) MFI of W6/32 APC binding for each sample. c) Dot plots showing leukocytes where
CD14 is plotted on the y-axis and peptide-FITC is plotted on the x-axis. Numbers to the right of the gates show the percentage of cells within
the gate. Plots show standard error of the mean.
Greene et al. BMC Immunology 2011, 12:39
http://www.biomedcentral.com/1471-2172/12/39
Page 14 of 17
different responses than a CD4 T cell-tropic virus expres-
sing similar protein sequences in macaques.
This may have particular implications for SIV, the
dominant experimental model for studying HIV patho-
genesis. SIV is known to have various tropisms that shift
throughout infection. SIVmac239 is a CCR5-tropic virus
and initially infects effector CD4 T cells. These cells are
massively depleted in the gut during the first weeks of
infection [31]. As SIV continues replicating it switches
tropism over time to begin infecting CD4 T cells with
other memory phenotypes [6]. The virus is also capable
of infecting macrophages, the tissue-resident, lineage des-
cendants of CD14+ monocytes. It is unclear how the
tropism of the virus might affect the CD8+ T cell
responses generated within these individuals. Our results
suggest that different viral targets may elicit different
SIV-specific CD8+ T cells due to differences in MHC
class I expression. This may also have a profound impact
on vaccination and the immune responses generated
depending on the cells targeted by the vaccine regimen.
Still, it is important to note the macaque MHC class I
region differs from the human class I region in several
ways. Intriguingly, macaques can express more than three
times the number of class I transcripts as humans [1]. In
addition to MHC diversity at the population level, there
are several studies that suggest expressing more total
alleles is advantageous in host pathogen interactions, a
phenomenon known as the heterozygote advantage
[32-41]. If having more MHC class I alleles is advanta-
geous, it is important to understand why humans do not
have additional MHC class I alleles on each chromosome.
Some research suggests that having additional MHC class
I alleles leads to loss of certain CD8+ T cells that are self-
reactive, thus limiting the repertoire of T cells [42]. These
issues are further confounded in light of macaques expres-




































































































































































** ** ** **
Figure 8 Measuring protein expression of Mafa-B*075:01 and Mafa-A1*063:01 by fluorescent peptide. Mafa-B*075:01 fAL9, Mafa-
A1*063:01 fSW9 and non-specific peptide fYL9 were used to examine protein expression in six leukocyte subsets in the PBMC. a) Relative
expression was calculated as previously described. A student’s T-test was used to analyze the differences in MHC expression between select
leukocyte subsets in the M3/M3 animals. The * symbols above each column indicate which columns were compared. (* p = 0.002; ** p = 0.009)
b) Measuring total MHC class I expression by MFI of W6/32 APC binding for each subpopulation. The * symbols above each column indicate
which columns were compared. (* p = 0.01) Plots show standard error of the mean.
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expression of MHC class I alleles that we observed in the
macaque may represent an evolutionary adaptation to
accommodate the large number of alleles expressed in
these animals.
Conclusions
Ultimately these results demonstrate that certain alleles in
the macaque MHC class I are expressed differentially in
distinct leukocyte subsets. Additionally, these differences
are conserved across multiple haplotypes and species, sug-
gesting there may be functional significance to this differ-
ential expression. Furthermore MHC class I known to
restrict CD8+ T cell responses during SIV infection also
appear to be differentially expressed providing evidence
that this phenomenon is not unique to the alleles we iden-
tified by sequence analysis and may be a universal aspect
of macaque MHC class I expression. We believe this
demonstrates the first example of differential classical
MHC class I expression in primates.
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